Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.
Zanchetta
J R
JR
Instituto de Investigaciones Metabolicas and USAL University School of Medicine, Buenos Aires, Argentina.
Bogado
C E
CE
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D002118:Calcium / Q000097:blood / Q000652:urine; D003404:Creatinine / Q000652:urine; D005260:Female; D005272:Femur Neck / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood / Q000150:complications*; D008159:Lumbar Vertebrae / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors
D010281:Parathyroid Hormone; D010710:Phosphates; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D003404:Creatinine; D000469:Alkaline Phosphatase; D002118:Calcium